Navigating Treatment Choices for Metastatic Castration-Sensitive Prostate Cancer
In a podcast, Cleveland Clinic oncologist Christopher Wee discusses how clinicians guide patients through treatment decisions for metastatic castration-sensitive prostate cancer. He covers treatment intensification, choosing between doublet and triplet therapy, and incorporating patient preferences and genomic testing.
The standard foundation for treating metastatic castration-sensitive prostate cancer remains androgen deprivation therapy. Recent clinical shifts advocate adding a second agent, typically an androgen receptor pathway inhibitor, to intensify treatment. For patients with high-volume disease, evidence from the CHAARTED trial supports incorporating chemotherapy alongside these therapies.
Clinicians also monitor two distinct progression patterns: rising PSA levels without visible new lesions, or actual tumor growth on imaging. These differing trajectories influence whether immediate treatment adjustments are necessary. The podcast series highlights how physicians weigh these clinical factors with patient preferences to guide shared decision-making.
This ongoing dialogue about treatment intensification could significantly impact patients newly diagnosed with advanced prostate cancer. As options expand, patients may face more complex trade-offs between survival benefits and quality-of-life impacts. The emphasis on shared decision-making and genomic testing may empower patients to align therapies with personal values, though it could also widen disparities if access to specialized oncology expertise remains uneven.